PDF(Pubmed)
Abstract：
This study compares the effectiveness of Conbercept and Aflibercept in treating neovascular age-related macular degeneration (nAMD). Conducted at the First Affiliated Hospital of Chongqing Medical University\'s Ophthalmology Department (May 2020-May 2023), this prospective study enrolled 159 nAMD patients. Participants were randomly divided into two groups: one receiving 0.5 mg Conbercept and the other 2 mg Aflibercept intravitreal injections. Over 12 months, the study, employing a Treat-and-Extend (T&E) regimen, assessed Best-Corrected Visual Acuity (BCVA), Central Retinal Thickness (CRT) changes and injection frequency. Of the 159 patients, 137 (149 eyes) completed the study. No significant age difference was found between the groups (P = 0.331). After 12 months, BCVA improved similarly in both groups (Conbercept: 52.8 ± 18.9, Aflibercept: 52.0 ± 19.7 letters; P = 0.820). CRT reduction was also comparable (Conbercept: 246.3 ± 82.8 µm, Aflibercept: 275.9 ± 114.3 µm; P = 0.079). Injection frequencies averaged 6.9 ± 0.7 (Conbercept) and 6.7 ± 0.7 (Aflibercept; P = 0.255). Subtype analysis revealed Type 1 MNV had higher baseline BCVA and lower CRT, with more frequent injections compared to other types. Both Conbercept and Aflibercept are clinically similar in efficacy for nAMD, with the T&E regimen proving therapeutically effective and potentially reducing patient costs. Anti-VEGF treatment efficacy varies across nAMD subtypes, indicating a potential benefit in tailored treatments for specific subtypes.Clinical trial registration number NCT05539235 (Protocol Registration and Results System).
摘要：
这项研究比较了康柏西普和阿柏西普治疗新生血管性年龄相关性黄斑变性（nAMD）的有效性。在重庆医科大学附属第一医院眼科进行（2020年5月至2023年5月），这项前瞻性研究纳入了159例nAMD患者.参与者被随机分为两组：一组接受0.5mg康柏西普，另一组接受2mg阿柏西普玻璃体内注射。超过12个月,研究,采用治疗和扩展(T&E)方案，评估最佳矫正视力（BCVA），视网膜中央厚度(CRT)变化和注射频率。159名患者中,137（149眼）完成了研究。组间年龄差异无统计学意义(P=0.331)。12个月后,两组的BCVA改善相似（Conbercept：52.8±18.9，Aflibercept：52.0±19.7字母；P=0.820）。CRT减少量也相当(Conbercept：246.3±82.8µm，阿柏西普：275.9±114.3µm；P=0.079）。注射频率平均为6.9±0.7(康柏西普)和6.7±0.7(阿柏西普;P=0.255)。亚型分析显示1型MNV具有较高的基线BCVA和较低的CRT,与其他类型相比，更频繁的注射。康柏西普和阿柏西普对nAMD的疗效在临床上相似，T&E方案证明治疗有效，并有可能降低患者成本。抗VEGF治疗效果因nAMD亚型而异，表明针对特定亚型的定制治疗具有潜在的益处。临床试验登记号NCT05539235(方案登记和结果系统)。
